Navigation Links
Nuvelo Announces Presentation on NU206 at 2007 American Association,for Cancer Research Annual Meeting

SAN CARLOS, Calif., April 04, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that preclinical data evaluating the mechanism of action and role of NU206 (R-Spondin1) as a specific and potent stimulator of the gastrointestinal (GI) epithelial cells will be presented in an educational session at the 2007 American Association for Cancer Research (AACR) Annual Meeting taking place at the Los Angeles Convention Center in Los Angeles, CA, April 14-18, 2007.

    The presentation details are as follows:

          Date/Time: Saturday, April 14, 2007, 8:00-10:00 a.m. PDT

          Location: Room 403 A-B, Los Angeles Convention Center

          Session/Abstract Title: Therapeutic Cancer Targets in the Wnt

          Pathway/R-Spondin, novel regulators of the Wnt/b-catenin signaling


    About NU206

NU206, also known as human R-spondin1, is a recombinant, secreted protein that has the potential to act as a potent and highly specific growth factor of GI epithelial cells. In early animal model studies, NU206 promoted growth and repair of these tissues in models of radiation treatment or chemotherapy, as well as in animal models of inflammatory bowel disease and short bowel syndrome. A publication in the August 2005 issue of Science described results from studies in animal models of mucositis, where NU206 was shown to diminish symptoms of mucositis, including diarrhea and weight loss.

About Nuvelo and Kirin's Joint Collaborative Effort

Scientists from Nuvelo and Kirin worked together to identify and characterize NU206 as part of a collaboration focused on the discovery of novel, secreted proteins. NU206 is the first compound to enter preclinical studies from this program. Nuvelo signed a collaboration agreement with Kirin in April 2005 to develop NU206. Under the agreement, Nuvelo leads worldwide development, manufacturing and commercialization and all operating expenses and p
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/2/2008)...S, October 2 /- Pharmaleads has obtai...authorization to perform a single,ascending dose P...,treatment of neuropathic pain., Neuropathic pain...ted,prevalence in the world,s population of up to ...y causes such as shingles, herpes, diabetes,antiv...
(Date:10/2/2008)...EC CITY, Oct. 2 / AEterna Z...biopharmaceutical company focused on,endocrine the...red the,second stage of patient recruitment for it... luteinizing hormone-releasing hormone (LHRH) agon...he second stage of patient,recruitment was taken f...
(Date:10/1/2008)...port the therapeutic potential of Amylin,s integra...sity pharmacotherapy, SAN DIEGO, Oct. 1 /PRNewswi...daq: AMLN ) today announced that new data for its...the 2008 Annual Scientific Meeting of The,Obesity ...y,s annual,meeting is one of the largest and most ...
(Date:10/1/2008)...FAX, Oct. 1 / ImmunoVaccine Technolog...oVax(TM) is showing positive,pre-clinical results,...,cancer and several infectious disease vaccine mod...d October 4th at the Ehrlich II conference in,Germ...ll also be reporting,on the capabilities of IVT,s ...
Breaking Medicine Technology:Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7ImmunoVaccine Technologies' DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases 2A new chemotherapeutic target for hepatocellular carcinoma 4581 1A new chemotherapeutic target for hepatocellular carcinoma 4581 2EpiVax receives JDRF program funding to develop diabetes drug using natural regulatory T cells 4579 1EpiVax receives JDRF program funding to develop diabetes drug using natural regulatory T cells 4579 2Frog study takes leaf out of natures book 965 1Frog study takes leaf out of natures book 965 2U M scientists find new causes for neurodegeneration 4576 1U M scientists find new causes for neurodegeneration 4576 2
...ented April 15th at EASL Conference in Barcelona,...,/PRNewswire-FirstCall/ - MIGENIX Inc. , a clinica..., has received new top-line results,confirming the...,2006) indicating evidence of clinical benefit, s...he oral alpha-glucosidase,inhibitor, celgosivir (M...
...ed in Recent Issue of Journal Blood, NEW YORK, Apr...rmaceuticals, Inc. (FWB: CA4), a developer of new ...her major health,threats, announced today the publ...to,s drug currently in clinical trials in,carcinoi...ruary,2007 issue of Blood, a peer-reviewed scienti...
Other Medicine Technology:New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8Callisto Pharmaceuticals Announces Publication of Research Article,on Atiprimod Preclinical Studies in Mantle Cell Lymphoma 2Callisto Pharmaceuticals Announces Publication of Research Article,on Atiprimod Preclinical Studies in Mantle Cell Lymphoma 3
(Date:10/6/2008)...t. 6 /PRNewswire/ -- Developed in collaboration wi...ades, CA is introducing,Revolutionary Breast Surfa...c Surgery office of Dr. Steve Laverson this week i...he first of its kind, and is based on,breakthrough...with,innovative proprietary software. The XS-300(T...
(Date:10/6/2008)...ct. 6 /PRNewswire/ -- The organizers of Informex a...e on Global Sourcing for the,Pharmaceutical Indust...inceton Marriott in New Jersey USA., The conferen... the,Global Sourcing Council, and boasts an unpara...e likes of Johnson & Johnson, Bristol Myers Squibb...
(Date:10/6/2008)... LegalView recently posted detailed inform...he potentially serious side effects caused by the ... the drug,s potential side effects are the develop... for young adult and child patients. , ...- LegalView, the number one resource for everythin...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
... malignant diseases which are responsible for numb...e been under taken// on this subject. A new study ...t in breast cancer by ethnicity. These findings ha...y of Colorado Health Sciences Center, Denver, and ...
...ever seem to leave the Hormone Replacement Therapy...d// report reversing its ‘notoriety’. Yet say som...over again. According to them, hormone replacement...re than 1,000 women in the UK from ovarian cancer ...
...ubside over Monday’s ghastly student massacre at...ner’ killer Cho Seung-Hui began to take form. Th...persons, could not be any stronger than this point...chiatrics ponder-where and when does one draw the ...
... sources, is touted as a more eco-friendly fuel, t...widespread// use of ethanol could actually pose a ... may not be that eco-friendly after all. The journ...r a new study at the Stanford University in the US...
Other Medicine News:Health News:Expert Warn- Odds Still Stacked Against Hormone Replacement Therapy 2Health News:Expert Warn- Odds Still Stacked Against Hormone Replacement Therapy 3Health News:Virginia Tech. Shooter -Human Rights or Innocent Lives 2Health News:Ethanol Could Be Damaging for Human Health, New Study Says 2Health News:Ethanol Could Be Damaging for Human Health, New Study Says 3
Para 12 Plus is a hematology control for the Abbott CELL-DYN 3000, 3200, and 3500/3700. Assay values are provided for the five-part white cell differential, as well as a three-part differential on th
Indicated to facilitate the intra-luminal placement of conventional guidewires beyond stenotic lesions, including chronic total coronary occlusions.
... 5X is a whole blood hematology control manufactur...0, and the Coulter AcT5diff instruments. The compo...differential, positioning the populations within t...he product offers 105-day closed-vial stability an...
...-Chex is a spinal and body fluid control with dist... the same manner as a patient sample, the white bl...trol is assayed for manual cell counting, the five...e two-part polymorphonuclear and mononuclear diffe...
Medicine Products: